{"id":3115,"date":"2017-04-19T15:00:46","date_gmt":"2017-04-19T19:00:46","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\/"},"modified":"2026-09-24T00:09:59","modified_gmt":"2026-09-24T04:09:59","slug":"gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/19\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\/","title":{"rendered":"GenSight Biologics invit\u00e9e  \u00e0 pr\u00e9senter  lors de prochaines conf\u00e9rences investisseurs"},"content":{"rendered":"\n<strong>Paris, 19 avril 2017, 7h30 CET \u2013<\/strong> GenSight Biologics (Euronext : SIGHT, FR0013183985, \u00e9ligible PEA- PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que des membres de son management participeront aux conf\u00e9rences investisseurs suivantes :\n\n<strong>5th Annual ARM Cell &amp; Gene Investor \u00a0Day<\/strong>\n<strong>27 avril 2017 \u2013 Boston, \u00a0MA<\/strong>\nBernard Gilly, Directeur G\u00e9n\u00e9ral, pr\u00e9sentera le 27 avril 2017 \u00e0 16:45 (heure locale), \u00e0 la State Room.\n\n<strong>Deutsche Bank 42nd Annual Health Care Conference<\/strong>\n<strong>3-4 mai 2017 \u2013 Boston, \u00a0MA<\/strong>\nBernard Gilly, Directeur G\u00e9n\u00e9ral, pr\u00e9sentera le 4 mai 2017 \u00e0 9:20 (heure locale), \u00e0 l\u2019InterContinental Boston Hotel.\n<h2>\u00c0 propos \u00a0de GenSight Biologics<\/h2>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (Mitochondrial Targeting Sequence, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. Le candidat m\u00e9dicament le plus avanc\u00e9 de GenSight Biologics, GS010, est en Phase III pour le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), une maladie mitochondriale rare qui conduit \u00e0 une perte irr\u00e9versible de la vue chez les adolescents et les jeunes adultes. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intravitr\u00e9enne dans chaque \u0153il.\n","protected":false},"excerpt":{"rendered":"<p>Paris, 19 avril 2017, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, FR0013183985, \u00e9ligible PEA- PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que des membres de son management participeront aux conf\u00e9rences investisseurs [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[],"post-year":[],"class_list":["post-3115","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors de prochaines conf\u00e9rences investisseurs - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/19\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors de prochaines conf\u00e9rences investisseurs - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, 19 avril 2017, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, FR0013183985, \u00e9ligible PEA- PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que des membres de son management participeront aux conf\u00e9rences investisseurs [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/19\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2017-04-19T19:00:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:09:59+00:00\" \/>\n<meta name=\"author\" content=\"editeur\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"editeur\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/04\\\/19\\\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/04\\\/19\\\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\\\/\"},\"author\":{\"name\":\"editeur\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\"},\"headline\":\"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors de prochaines conf\u00e9rences investisseurs\",\"datePublished\":\"2017-04-19T19:00:46+00:00\",\"dateModified\":\"2026-09-24T04:09:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/04\\\/19\\\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\\\/\"},\"wordCount\":314,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/04\\\/19\\\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/04\\\/19\\\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\\\/\",\"name\":\"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors de prochaines conf\u00e9rences investisseurs - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2017-04-19T19:00:46+00:00\",\"dateModified\":\"2026-09-24T04:09:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/04\\\/19\\\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/04\\\/19\\\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/04\\\/19\\\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors de prochaines conf\u00e9rences investisseurs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\",\"name\":\"editeur\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"caption\":\"editeur\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors de prochaines conf\u00e9rences investisseurs - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/19\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors de prochaines conf\u00e9rences investisseurs - GenSight Biologics","og_description":"Paris, 19 avril 2017, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, FR0013183985, \u00e9ligible PEA- PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que des membres de son management participeront aux conf\u00e9rences investisseurs [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/19\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\/","og_site_name":"GenSight Biologics","article_published_time":"2017-04-19T19:00:46+00:00","article_modified_time":"2026-09-24T04:09:59+00:00","author":"editeur","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"editeur","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/19\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/19\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\/"},"author":{"name":"editeur","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a"},"headline":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors de prochaines conf\u00e9rences investisseurs","datePublished":"2017-04-19T19:00:46+00:00","dateModified":"2026-09-24T04:09:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/19\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\/"},"wordCount":314,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/19\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/19\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\/","name":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors de prochaines conf\u00e9rences investisseurs - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2017-04-19T19:00:46+00:00","dateModified":"2026-09-24T04:09:59+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/19\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/19\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/19\/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors de prochaines conf\u00e9rences investisseurs"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a","name":"editeur","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","caption":"editeur"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3115"}],"version-history":[{"count":2,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3115\/revisions"}],"predecessor-version":[{"id":6405,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3115\/revisions\/6405"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3115"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3115"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3115"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3115"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}